A phase Ib/II study of niraparib combination therapies for the treatment of metastatic castration-resistant prostate cancer (NCT03431350).

Sumit K. Subudhi,Ana Aparicio,Amado J. Zurita,Bernard Doger,William Kevin Kelly,Avivit Peer,Dana E. Rathkopf,Lawrence Ivan Karsh,Jeffrey J. Tryon,Nishi Kothari,Xin Zhao,Eugene Zhu,Deborah Ricci,Namphuong Tran,Johann S. de Bono

A phase Ib/II study of niraparib combination therapies for the treatment of metastatic castration-resistant prostate cancer (NCT03431350).

2019

Sumit K. Subudhi
Ana Aparicio
Amado J. Zurita
Bernard Doger
William Kevin Kelly
Avivit Peer
Dana E. Rathkopf
Lawrence Ivan Karsh
Jeffrey J. Tryon
Nishi Kothari
Xin Zhao
Eugene Zhu
Deborah Ricci
Namphuong Tran
Johann S. de Bono

TPS5087Background: Assessing multiple therapies in a single clinical trial can facilitate the rapid identification of new agents for the treatment of patients with metastatic castration-resistant p...

Keywords:

Prostate cancer
Castration
Oncology
Pathology
Medicine
Internal medicine
castration resistant
Clinical trial
rapid identification

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations